Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03490032 · ClinicalTrials.gov registry record · Phase 1
68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)
A Phase 1 study, sponsored by Advanced Accelerator Applications.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT03490032 is a Phase 1 study that has completed, run by Advanced Accelerator Applications. The registered enrollment target is 30 participants.
The verdict
NCT03490032, a Phase 1 study, has completed, sponsored by Advanced Accelerator Applications.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This was an open-label, multicenter, single dose, Phase I/II study to evaluate the safety and tolerability of a single administration of 3 mega Becquerel (MBq)/kg, but not less than 150 MBq and not more than 250 MBq, of 68\^Ga-PSMA-R2 in adult male patients with biochemical relapse (BR) and metastatic prostate cancer (mPCa).
Interventions
- DRUG [68Ga]-PSMA-R2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-05-23 |
| Est. Completion | 2019-09-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03490032
The ClinicalTrials.gov registry entry for NCT03490032 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Advanced Accelerator Applications, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [68Ga]-PSMA-R2 is the first listed.
NCT03490032 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03490032 about?
NCT03490032 is a clinical study titled "68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)". This was an open-label, multicenter, single dose, Phase I/II study to evaluate the safety and tolerability of a single administration of 3 mega Becquerel (MBq)/kg, but not less than 150 MBq and not more than 250 MBq, of 68\^Ga-PSMA-R2 in adult male patients with biochemical relapse (BR) and metastat...
What is the current status of trial NCT03490032?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2018-05-23. Estimated completion is 2019-09-13.
What interventions are being tested in trial NCT03490032?
The interventions under investigation include: [68Ga]-PSMA-R2 (DRUG).
Who is sponsoring clinical trial NCT03490032?
This trial is sponsored by Advanced Accelerator Applications, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.